About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in San Francisco | 12,991 Studies Near You | Clareo Health

Clinical Trials LocationsSan Francisco

Clinical Trials in San Francisco

Discover 12,991 clinical trials near San Francisco, California. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 11041-11060 of 12,991 trials

COMPLETEDPhase 1< 1 mile

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

NCT00920907

The purpose of this clinical research study is to compare pharmacokinetics of ipilimumab manufactured by two different processes

Advanced Melanoma

Bristol-Myers Squibb99 participantsStarted Aug 2009

Los Angeles, California, United States • San Francisco, California, United States • Tampa, Florida, United States +4 more locations

COMPLETEDPhase 2< 1 mile

AST-120 Used to Treat Mild Hepatic Encephalopathy

NCT00867698

The purpose of this study is to determine whether AST-120 is safe and effective in the treatment of mild hepatic encephalopathy.

Mild Hepatic Encephalopathy

Ocera Therapeutics148 participantsStarted Mar 2009

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Fresno, California, United States +35 more locations

Find Trials by Condition in San Francisco

Breast Cancerin San Francisco Lung Cancerin San Francisco Prostate Cancerin San Francisco Colorectal Cancerin San Francisco Melanomain San Francisco Leukemiain San Francisco Lymphomain San Francisco Pancreatic Cancerin San Francisco Ovarian Cancerin San Francisco Brain Cancerin San Francisco

Data from ClinicalTrials.govTerms

COMPLETEDPhase 2< 1 mile

A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma

NCT00515697

The purpose of this study is to determine whether ramucirumab is effective treatment in participants with metastatic renal cell carcinoma who have developed progressive disease or become intolerant to tyrosine kinase inhibitor therapy.

Metastatic Renal Cell Carcinoma

Eli Lilly and Company39 participantsStarted Nov 2007

San Francisco, California, United States • Chicago, Illinois, United States • Metairie, Louisiana, United States +8 more locations

TERMINATEDPhase 310 miles

A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).

NCT00441558

To determine if long-term treatment with Flibanserin is safe and to monitor the effectiveness of Flibanserin in Women with HSDD that have already completed a previous study (511.70/71/.74/.75/.105) with Flibanserin.

Sexual Dysfunctions, Psychological

Sprout Pharmaceuticals, Inc1,723 participantsStarted Feb 2007

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Huntsville, Alabama, United States +193 more locations

COMPLETEDPhase 310 miles

12 / 48 Week Pivotal PFT vs PBO in COPD I

NCT00782210

This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD). The safety of BI 1744 CL inhalation solution delivered through the Respimat inhaler will also be compared to placebo.

Pulmonary Disease, Chronic Obstructive

Boehringer Ingelheim625 participantsStarted Nov 2008

Jasper, Alabama, United States • Berkeley, California, United States • Los Angeles, California, United States +51 more locations

COMPLETEDPhase 313 miles

Dapagliflozin DPPIV Inhibitor add-on Study

NCT00984867

This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin). The effect of dapagliflozin on weight and blood pressure will also be studied.

Type 2 Diabetes

AstraZeneca833 participantsStarted Oct 2009

Huntsville, Alabama, United States • Ozark, Alabama, United States • Anaheim, California, United States +85 more locations

COMPLETEDPhase 416 miles

A Multi-center Long Term Efficacy Trial of the GFX For Reduction of Glabellar Furrowing

NCT00611273

Long term efficacy study of GFX for patients undergoing reduction of glabellar furrowing

Glabellar Furrowing

Advanced Cosmetic Intervention260 participantsStarted Sep 2007

Beverly Hills, California, United States • San Mateo, California, United States • Tampa, Florida, United States +7 more locations

COMPLETEDPhase 221 miles

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

NCT00881530

The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2 diabetes mellitus.

Diabetes Mellitus, Type 2

Boehringer Ingelheim660 participantsStarted Mar 2009

Mission Viejo, California, United States • Spring Valley, California, United States • Walnut Creek, California, United States +134 more locations

TERMINATEDPhase 228 miles

Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

NCT00805467

The purpose of this new research study is to gain additional information about how safe and effective R935788 is over a longer period of time.

Rheumatoid Arthritis

AstraZeneca624 participantsStarted Aug 2008

La Jolla, California, United States • Palm Desert, California, United States • Palo Alto, California, United States +73 more locations

COMPLETEDPhase 328 miles

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

NCT00400153

The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered by the Respimat® inhaler (20 mcg), and COMBIVENT® MDI administered q.i.d on FEV1 at intervals over a treatment period of 12 weeks in patients with COPD. Specifically, non-inferiority of Combivent Respimat® to COMBIVENT® MDI in FEV1 AUC from 0 to 6 hours , superiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 0 to 4 hours, and non-inferiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 4 to 6 hours will be analyzed. In addition, steady state pharmacokinetics over one dosing interval following 4 weeks of therapy will be characterized in a subgroup of patients.

Pulmonary Disease, Chronic Obstructive

Boehringer Ingelheim1,480 participantsStarted Nov 2006

Birmingham, Alabama, United States • Jasper, Alabama, United States • Mobile, Alabama, United States +177 more locations

TERMINATEDPhase 242 miles

Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.

NCT00530166

The purpose of this study is to assess the effectiveness of JNJ-18054478 measured by the percent change from baseline in Forced Expiratory Volume in one Second (FEV1) after 12 weeks of therapy in patients with persistent asthma.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.26 participantsStarted Jul 2007

Scottsdale, Arizona, United States • Long Beach, California, United States • Los Angeles, California, United States +33 more locations

COMPLETEDPhase 275 miles

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

NCT01748877

The purpose of this study is to investigate whether NXN-462, a selective nNOS inhibitor, is effective in reducing pain levels in patients with post-herpetic neuralgia.

Post Herpetic Neuralgia

NeurAxon Inc.188 participantsStarted Jan 2013

Phoenix, Arizona, United States • Los Angeles, California, United States • Sacramento, California, United States +22 more locations

COMPLETEDPhase 2336 miles

Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone

NCT00995345

The purpose of this study is to assess the safety and effectiveness of KRP-104 on glycemic control in patients with type 2 diabetes inadequately controlled on metformin alone.

Type 2 Diabetes

ActivX Biosciences, Inc.403 participantsStarted Oct 2009

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +42 more locations

COMPLETEDPhase 2340 miles

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

NCT00110305

The purpose of this study is to evaluate the dose-response relationship of antiviral activity after 48 weeks treatment with 3 different dose regimens of TMC278.

Human Immunodeficiency Virus Type 1

Tibotec Pharmaceuticals, Ireland368 participantsStarted Jun 2005

Beverly Hills, California, United States • Washington D.C., District of Columbia, United States • Orlando, Florida, United States +37 more locations

COMPLETEDPhase 3347 miles

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

NCT00113607

The purpose of the study is to compare the progression-free survival (PFS) of the combination of trabectedin + DOXIL with DOXIL monotherapy in patients with ovarian cancer.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.672 participantsStarted Apr 2005

Mobile, Alabama, United States • Tucson, Arizona, United States • Los Angeles, California, United States +108 more locations

COMPLETEDPhase 1347 miles

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

NCT01468350

A double-blind, placebo-controlled, crossover study in subjects with cerebral palsy (CP) to evaluate the safety and tolerability and the effect of dalfampridine extended release (ER) tablets on sensorimotor function

Cerebral Palsy (CP)

Acorda Therapeutics35 participantsStarted Dec 2011

Birmingham, Alabama, United States • Downey, California, United States • Los Angeles, California, United States +8 more locations

COMPLETEDPhase 3347 miles

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

NCT01159600

The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient glycaemic control.

Diabetes Mellitus, Type 2

Boehringer Ingelheim1,504 participantsStarted Jul 2010

Birmingham, Alabama, United States • Tempe, Arizona, United States • Huntington Park, California, United States +145 more locations

COMPLETEDPhase 2365 miles

Dose Range Finding Study of Fedovapagon in Men With Nocturia

NCT01656239

The purpose of this study is to determine the dose level(s) of fedovapagon which result in a decrease in the mean nocturnal void frequency.

Vantia Ltd358 participantsStarted Aug 2012

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Mobile, Alabama, United States +53 more locations

COMPLETED655 miles

Ondansetron and the QT Interval In Adult Emergency Department Patients

NCT01759420

The purpose of this study is to assess the use of the medication ondansetron (zofran) in the emergency department. There are studies of the ability of ondansetron to cause a prolongation in the QT interval (a certain measurement on an EKG) in anesthesia and cancer patients, but not on emergency department patients. This is an observational study where patients that are going to receive the anti-nausea medicine ondansetron in the emergency department will have an EKG performed every 2 minutes for 20 minutes to determine if the QT interval prolongs and returns to normal in that time period. Any serious outcomes will be reported. There is expected to be no adverse outcomes from this routinely used medication.

C.R.Darnall Army Medical Center28 participantsStarted Dec 2012

Fort Hood, Texas, United States • Tacoma, Washington, United States

COMPLETEDNA655 miles

Effects of School Gardens on Children's Diet, Nutritional Knowledge, Etc.

NCT02166034

The purpose of this study is to determine whether school gardens influence children's dietary intake, nutritional knowledge, and other outcomes.

Cornell University3,531 participantsStarted Aug 2011

Little Rock, Arkansas, United States • Osceola, Iowa, United States • Ithaca, New York, United States +1 more locations

PreviousPage 553 of 650Next

Diabetes

in San Francisco

Heart Diseasein San Francisco